Autopsy report · NCT04026334

Evaluation of V.A.C. VERAFLO CLEANSE CHOICE™ Dressing Using Normal Saline to Promote Increased Healthy Wound Bed Tissue

“Insufficient subject accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

3M

Sponsor type

Industry

Conditions

Wound; Wound Heal; Wounds and Injuries; Granulation Tissue; Negative-pressure Wound Therapy

Interventions

V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
  “insufficient accrual rate” (83% match in meaning)
• Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
  “insufficient rate of accrual” (81% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (76% match in meaning)
• Factors Affecting Perioperative Outcomes
  “No subject accrual” (73% match in meaning)
• Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension
  “Low subject accrual” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.